STK10

Summary

STK10 (serine/threonine kinase 10, HGNC:11388) is a protein-coding gene on chromosome 5q35.1, encoding Serine/threonine-protein kinase 10 (O94804). Serine/threonine-protein kinase involved in regulation of lymphocyte migration.

This gene encodes a member of the Ste20 family of serine/threonine protein kinases, and is similar to several known polo-like kinase kinases. The protein can associate with and phosphorylate polo-like kinase 1, and overexpression of a kinase-dead version of the protein interferes with normal cell cycle progression. The kinase can also negatively regulate interleukin 2 expression in T-cells via the mitogen activated protein kinase kinase 1 pathway.

Source: NCBI Gene 6793 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 171 total
• Druggable target: yes — 79 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005990

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11388
Approved symbol	STK10
Name	serine/threonine kinase 10
Location	5q35.1
Locus type	gene with protein product
Status	Approved
Aliases	LOK, PRO2729
Ensembl gene	ENSG00000072786
Ensembl biotype	protein_coding
OMIM	603919
Entrez	6793

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 10 protein_coding, 8 retained_intron, 6 protein_coding_CDS_not_defined

ENST00000176763, ENST00000517360, ENST00000517381, ENST00000517524, ENST00000517527, ENST00000517775, ENST00000518267, ENST00000519269, ENST00000519441, ENST00000519710, ENST00000520476, ENST00000521322, ENST00000522879, ENST00000522936, ENST00000523603, ENST00000523615, ENST00000877786, ENST00000877787, ENST00000877788, ENST00000877789, ENST00000877790, ENST00000916144, ENST00000916145, ENST00000916146

RefSeq mRNA: 1 — MANE Select: NM_005990 NM_005990

CCDS: CCDS34290

Canonical transcript exons

ENST00000176763 — 19 exons

Exon	Start	End
ENSE00000769446	172156624	172156788
ENSE00000812846	172187887	172188224
ENSE00000973051	172096426	172096560
ENSE00000973052	172093412	172093960
ENSE00000973055	172082326	172082505
ENSE00000973060	172055588	172055776
ENSE00000973061	172054569	172054694
ENSE00000973062	172052929	172053042
ENSE00001003610	172064720	172064812
ENSE00001003619	172061139	172061268
ENSE00001003620	172042079	172045022
ENSE00001507187	172082961	172083084
ENSE00001507188	172090232	172090362
ENSE00003484309	172106620	172106814
ENSE00003494266	172107780	172107852
ENSE00003494555	172117481	172117630
ENSE00003560084	172057349	172057473
ENSE00003589902	172127373	172127421
ENSE00003645837	172105656	172105737

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 98.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.9293 / max 1085.8611, expressed in 1794 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
64854	21.0184	1778
64855	4.6442	1414
64853	3.7660	1062
64852	0.3482	142
64841	0.0582	20
64856	0.0581	13
64842	0.0362	11

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	98.83	gold quality
sural nerve	UBERON:0015488	97.36	gold quality
blood	UBERON:0000178	97.35	gold quality
leukocyte	CL:0000738	96.98	gold quality
monocyte	CL:0000576	96.93	gold quality
mononuclear cell	CL:0000842	96.88	gold quality
spleen	UBERON:0002106	96.01	gold quality
cerebellar hemisphere	UBERON:0002245	95.95	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.80	gold quality
cerebellar cortex	UBERON:0002129	95.77	gold quality
bone marrow cell	CL:0002092	94.70	gold quality
cerebellum	UBERON:0002037	93.85	gold quality
upper lobe of left lung	UBERON:0008952	93.07	gold quality
lymph node	UBERON:0000029	92.94	gold quality
vermiform appendix	UBERON:0001154	92.55	gold quality
upper lobe of lung	UBERON:0008948	92.39	gold quality
right lung	UBERON:0002167	91.59	gold quality
bone marrow	UBERON:0002371	91.23	gold quality
tibial nerve	UBERON:0001323	91.20	gold quality
omental fat pad	UBERON:0010414	90.80	gold quality
peritoneum	UBERON:0002358	90.73	gold quality
adipose tissue of abdominal region	UBERON:0007808	90.07	gold quality
left testis	UBERON:0004533	90.00	gold quality
right testis	UBERON:0004534	89.81	gold quality
skin of leg	UBERON:0001511	89.61	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.37	gold quality
bone element	UBERON:0001474	89.08	gold quality
caecum	UBERON:0001153	88.76	gold quality
apex of heart	UBERON:0002098	88.56	gold quality
testis	UBERON:0000473	88.30	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	9.48
E-GEOD-110499	no	268.00
E-MTAB-6379	no	265.25
E-CURD-112	no	2.57
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

92 targeting STK10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-548BB-3P	99.86	70.58	4354

Literature-anchored findings (GeneRIF, showing 9)

• Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T-cells (PMID:11903060)
• Stk10 is a novel polo-like kinase kinase that cooperates with hSlk to regulate Plk1 function in human cells (PMID:12639966)
• These studies identify a new ERM kinase of importance in lymphocytes and confirm the role of ezrin-radixin-moesin phosphorylation in regulating cell shape and motility. (PMID:19255442)
• genetic polymorphism is associated with aspirin-intolerant asthma in a Korean population (PMID:21905501)
• It was shown that lymphocyte-oriented and STE20 kinase were sufficient to restrict ezrin function to the apical domain. Both kinases were enriched in microvilli and locally activated there. (PMID:23209304)
• STK10 functions as a tumor suppressor gene, and dysfunction of STK10 activity either through polymorphism or somatic mutations may confer anti-apoptotic effects contributing to carcinogenesis. (PMID:23842845)
• The gene signature of OPA1, CTSA, NDUFA1, STK10 and PRDX1 was able to identify patients post-implant with a sensitivity of 91% and a specificity of 86% in discrimination between post-implant group and healthy controls. (PMID:27177495)
• Binding of phosphatidylinositol 4,5-biphosphate to ezrin induces a conformational change permitting the insertion of the LOK C-terminal domain to wedge apart the membrane and F-actin-binding domains of ezrin. The N-terminal LOK kinase domain can then access a site 40 residues distal from the consensus sequence that collectively direct phosphorylation of the appropriate threonine residue. (PMID:28430576)
• Systematic analysis of prognostic significance, functional enrichment and immune implication of STK10 in acute myeloid leukemia. (PMID:35501867)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	stk10	ENSDARG00000101894
mus_musculus	Stk10	ENSMUSG00000020272
rattus_norvegicus	Stk10	ENSRNOG00000004217

Paralogs (35): MAP3K14 (ENSG00000006062), MAP4K3 (ENSG00000011566), MAP4K5 (ENSG00000012983), MAP2K3 (ENSG00000034152), SLK (ENSG00000065613), MAP4K4 (ENSG00000071054), PAK3 (ENSG00000077264), STRADB (ENSG00000082146), MAP3K1 (ENSG00000095015), STK4 (ENSG00000101109), PAK5 (ENSG00000101349), STK24 (ENSG00000102572), STK3 (ENSG00000104375), MAP4K1 (ENSG00000104814), MAP3K8 (ENSG00000107968), MAP2K6 (ENSG00000108984), NEK4 (ENSG00000114904), STK25 (ENSG00000115694), NRK (ENSG00000123572), PAK4 (ENSG00000130669), STK26 (ENSG00000134602), TAOK3 (ENSG00000135090), PAK6 (ENSG00000137843), MINK1 (ENSG00000141503), PAK1 (ENSG00000149269), TAOK2 (ENSG00000149930), TNIK (ENSG00000154310), TAOK1 (ENSG00000160551), MAP4K2 (ENSG00000168067), OXSR1 (ENSG00000172939), MAP3K19 (ENSG00000176601), PAK2 (ENSG00000180370), SBK2 (ENSG00000187550), STK39 (ENSG00000198648), STRADA (ENSG00000266173)

Protein

Protein identifiers

Serine/threonine-protein kinase 10 — O94804 (reviewed: O94804)

Alternative names: Lymphocyte-oriented kinase

All UniProt accessions (2): O94804, H0YB71

UniProt curated annotations — full annotation on UniProt →

Function. Serine/threonine-protein kinase involved in regulation of lymphocyte migration. Phosphorylates MSN, and possibly PLK1. Involved in regulation of lymphocyte migration by mediating phosphorylation of ERM proteins such as MSN. Acts as a negative regulator of MAP3K1/MEKK1. May also act as a cell cycle regulator by acting as a polo kinase kinase: mediates phosphorylation of PLK1 in vitro; however such data require additional evidences in vivo.

Subunit / interactions. Homodimer; homodimerization is required for activation segment autophosphorylation.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in rapidly proliferating tissues (spleen, placenta, and peripheral blood leukocytes). Also expressed in brain, heart, skeletal muscle, colon, thymus, kidney, liver, small intestine and lung.

Post-translational modifications. Autophosphorylates following homodimerization, leading to activation of the protein.

Disease relevance. Testicular germ cell tumor (TGCT) [MIM:273300] A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. The disease may be caused by variants affecting the gene represented in this entry.

Activity regulation. Inhibited by the pyrrole-indolinone inhibitor SU11274 (K00593): intercalates between the ATP-binding Lys-65 and alpha-C glutamate (Glu-81), resulting in a partial disordering of the lysine side chain. Also specifically inhibited by erlotinib. Slightly inhibited by gefitinib.

Miscellaneous. Inhibition by erlotinib, an orally administered EGFR tyrosine kinase inhibitor used for treatment, enhances STK10-dependent lymphocytic responses, possibly leading to the aggravation of skin inflammation observed upon treatment by erlotinib.

Similarity. Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. STE20 subfamily.

RefSeq proteins (1): NP_005981* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR022165	PKK	Family
IPR042743	STK10_STKc	Domain
IPR051585	STE20_Ser/Thr_Kinases	Family

Pfam: PF00069, PF12474

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (72 total): helix 15, sequence variant 12, modified residue 10, strand 9, region of interest 7, turn 5, compositionally biased region 4, sequence conflict 3, binding site 2, chain 1, domain 1, active site 1, mutagenesis site 1, coiled-coil region 1

Structure

Experimental structures (PDB)

14 structures.

PDB	Method	Resolution (Å)
6EIM	X-RAY DIFFRACTION	1.43
7QGP	X-RAY DIFFRACTION	1.9
2J7T	X-RAY DIFFRACTION	2
4EQU	X-RAY DIFFRACTION	2
6HXF	X-RAY DIFFRACTION	2.09
4BC6	X-RAY DIFFRACTION	2.2
5AJQ	X-RAY DIFFRACTION	2.2
6GTT	X-RAY DIFFRACTION	2.25
5OWR	X-RAY DIFFRACTION	2.3
4AOT	X-RAY DIFFRACTION	2.33
6I2Y	X-RAY DIFFRACTION	2.56
4USE	X-RAY DIFFRACTION	2.65
5OWQ	X-RAY DIFFRACTION	2.7
4USD	X-RAY DIFFRACTION	3.05

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O94804-F1	74.82	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 157 (proton acceptor)

Ligand- & substrate-binding residues (2): 42–50; 65

Post-translational modifications (10): 13, 20, 191, 438, 450, 454, 485, 514, 549, 952

Mutagenesis-validated functional residues (1):

Position	Phenotype
65	loss of kinase activity.

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013026	RHOB GTPase cycle
R-HSA-9013106	RHOC GTPase cycle
R-HSA-162582	Signal Transduction
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-194315	Signaling by Rho GTPases
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 312 (showing top): MODULE_97, REACTOME_INNATE_IMMUNE_SYSTEM, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, YAGI_AML_WITH_INV_16_TRANSLOCATION, GNF2_CASP8, GOCC_SECRETORY_GRANULE, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, MODULE_182, GGGTGGRR_PAX4_03, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_REGULATION_OF_MONONUCLEAR_CELL_MIGRATION, GOBP_CELL_CELL_ADHESION, GOBP_LEUKOCYTE_MIGRATION, FINETTI_BREAST_CANCER_KINOME_GREEN, XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_UP

GO Biological Process (5): protein phosphorylation (GO:0006468), intracellular signal transduction (GO:0035556), protein autophosphorylation (GO:0046777), lymphocyte aggregation (GO:0071593), regulation of lymphocyte migration (GO:2000401)

GO Molecular Function (10): protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (8): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), nuclear body (GO:0016604), specific granule membrane (GO:0035579), extracellular exosome (GO:0070062), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
RHO GTPase cycle	3
Innate Immune System	1
Immune System	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
intracellular anatomical structure	2
protein kinase activity	2
phosphorylation	1
protein modification process	1
signal transduction	1
protein phosphorylation	1
leukocyte aggregation	1
regulation of mononuclear cell migration	1
lymphocyte migration	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
protein binding	1
identical protein binding	1
protein dimerization activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
nucleoplasm	1
intracellular membraneless organelle	1
secretory granule membrane	1
specific granule	1
extracellular vesicle	1

Protein interactions and networks

STRING

728 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STK10	EZR	P15311	494
STK10	MSN	P26038	464
STK10	RDX	P35241	464
STK10	RHOA	P06749	457
STK10	PLK1	P53350	434
STK10	IFNG	P01579	420
STK10	ERBB2	P04626	397
STK10	ERVMER34-1	Q9H9K5	355
STK10	NHERF1	O14745	348
STK10	C5orf52	A6NGY3	323
STK10	UBTD2	Q8WUN7	311
STK10	NR3C1	P04150	297
STK10	NHERF2	Q15599	289
STK10	ARHGEF37	A1IGU5	283
STK10	ARHGEF38	Q9NXL2	279

IntAct

23 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
STK10	STK10	psi-mi:“MI:0407”(direct interaction)	0.620
MAP1LC3A	STK10	psi-mi:“MI:0407”(direct interaction)	0.440
STK10	NONO	psi-mi:“MI:0915”(physical association)	0.400
	STK10	psi-mi:“MI:0915”(physical association)	0.400
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
TANK	CNOT1	psi-mi:“MI:0914”(association)	0.350
RIPK2	CNOT1	psi-mi:“MI:0914”(association)	0.350
CAMK4	CNOT1	psi-mi:“MI:0914”(association)	0.350
BORCS8	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
TBC1D9	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
MILR1	SBNO1	psi-mi:“MI:0914”(association)	0.350
MRPL53		psi-mi:“MI:0914”(association)	0.350
	TBKBP1	psi-mi:“MI:0914”(association)	0.350
	PSMD12	psi-mi:“MI:0914”(association)	0.350
LAMP1	PIPSL	psi-mi:“MI:2364”(proximity)	0.270
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270
CDH5	ESYT2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (74): STK10 (Affinity Capture-RNA), STK10 (Affinity Capture-RNA), STK10 (Affinity Capture-RNA), STK10 (Affinity Capture-RNA), KIFC1 (Co-fractionation), STK10 (Affinity Capture-MS), STK10 (Affinity Capture-RNA), STK10 (Affinity Capture-RNA), STK10 (Affinity Capture-RNA), STK10 (Proximity Label-MS), STK10 (Proximity Label-MS), STK10 (Affinity Capture-RNA), STK10 (Affinity Capture-MS), STK10 (Affinity Capture-MS), NONO (Proximity Label-MS)

ESM2 similar proteins: A0JMA8, A5WW21, A8WVU9, B0S6J3, B7ZR30, E1BK52, E7F187, E9PTG8, F1NBT0, G5EFD2, O01583, O08815, O43150, O54874, O54988, O55092, O55098, O88664, O94804, P46549, Q08CX1, Q0IHQ8, Q22908, Q3UU96, Q4G3H4, Q53UA7, Q5F2E8, Q5R4F3, Q5U245, Q5VT25, Q5ZJB4, Q619T5, Q6DD27, Q6GPK9, Q6NU21, Q7L7X3, Q7SIG6, Q7SY52, Q7TT49, Q7TT50

Diamond homologs: A0A194VNL2, A0A1S4CGX4, A4K2M3, A4K2P5, A4K2Q5, A4K2S1, A4K2T0, A4K2W5, A4K2Y1, A8XJW8, A9RWC9, A9S5R3, A9SR33, B0XPE4, C4YLK8, E1BK52, F1NBT0, G4N6Z6, G4NEB8, G5EDF7, O00506, O09110, O14733, O54748, O80396, O94804, O95819, P06784, P08018, P0CY25, P10506, P29678, P31938, P32490, P32491, P33886, P36506, P36507, P45985, P46734

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
STK10	“up-regulates activity”	MSN	phosphorylation
STK10	“up-regulates activity”	EZR	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

171 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	136
Likely benign	5
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

3620 predictions. Top by Δscore:

Variant	Effect	Δscore
5:172045019:GAGC:G	acceptor_gain	1.0000
5:172045020:AGC:A	acceptor_gain	1.0000
5:172045020:AGCC:A	acceptor_loss	1.0000
5:172045021:GC:G	acceptor_gain	1.0000
5:172045022:CC:C	acceptor_gain	1.0000
5:172045022:CCT:C	acceptor_loss	1.0000
5:172045023:C:CC	acceptor_gain	1.0000
5:172045023:CTA:C	acceptor_loss	1.0000
5:172052924:GTTA:G	donor_loss	1.0000
5:172052926:TAC:T	donor_loss	1.0000
5:172052928:CCTT:C	donor_gain	1.0000
5:172052931:T:A	donor_gain	1.0000
5:172053039:CATT:C	acceptor_gain	1.0000
5:172053041:TT:T	acceptor_gain	1.0000
5:172053041:TTCTG:T	acceptor_loss	1.0000
5:172053042:TCTGG:T	acceptor_loss	1.0000
5:172053043:C:CC	acceptor_gain	1.0000
5:172053043:CTGGA:C	acceptor_loss	1.0000
5:172053044:T:G	acceptor_loss	1.0000
5:172053049:C:CT	acceptor_gain	1.0000
5:172053056:C:CT	acceptor_gain	1.0000
5:172053056:C:T	acceptor_gain	1.0000
5:172054566:TA:T	donor_loss	1.0000
5:172054567:AC:A	donor_loss	1.0000
5:172054568:C:CT	donor_loss	1.0000
5:172054690:GAGAA:G	acceptor_gain	1.0000
5:172054691:AGAA:A	acceptor_gain	1.0000
5:172054692:GAA:G	acceptor_gain	1.0000
5:172054693:AA:A	acceptor_gain	1.0000
5:172054695:C:CC	acceptor_gain	1.0000

AlphaMissense

6454 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:172083073:A:G	L566P	1.000
5:172090325:C:G	R531P	1.000
5:172090326:G:T	R531S	1.000
5:172106674:A:T	V245D	1.000
5:172106728:A:G	L227P	1.000
5:172106740:A:G	L223P	1.000
5:172106745:C:A	W221C	1.000
5:172106745:C:G	W221C	1.000
5:172106747:A:G	W221R	1.000
5:172106747:A:T	W221R	1.000
5:172106753:C:G	D219H	1.000
5:172106797:A:T	V204D	1.000
5:172106812:A:C	M199R	1.000
5:172106812:A:G	M199T	1.000
5:172106812:A:T	M199K	1.000
5:172106814:C:A	W198C	1.000
5:172106814:C:G	W198C	1.000
5:172107781:A:G	W198R	1.000
5:172107781:A:T	W198R	1.000
5:172107784:A:C	Y197D	1.000
5:172107784:A:G	Y197H	1.000
5:172107786:G:T	P196H	1.000
5:172107792:C:T	G194D	1.000
5:172107793:C:G	G194R	1.000
5:172107797:G:C	F192L	1.000
5:172107797:G:T	F192L	1.000
5:172107799:A:G	F192L	1.000
5:172107844:C:G	G177R	1.000
5:172107848:G:C	D175E	1.000
5:172107848:G:T	D175E	1.000

dbSNP variants (sampled 300 via entrez): RS1000033992 (5:172142280 C>A), RS1000038065 (5:172056360 G>C), RS1000064835 (5:172133580 G>A), RS1000070058 (5:172177270 G>C), RS1000082564 (5:172095875 A>G), RS1000096966 (5:172133941 G>C), RS1000105369 (5:172061242 C>T), RS1000137865 (5:172061039 A>C,T), RS1000142524 (5:172145496 C>T), RS1000145432 (5:172098755 T>G), RS1000159789 (5:172173543 G>A,T), RS1000174272 (5:172055746 G>A), RS1000187145 (5:172136868 C>T), RS1000190220 (5:172101081 C>T), RS1000197703 (5:172108811 G>T)

Disease associations

OMIM: gene MIM:603919 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST006658_10	Longevity	9.000000e-06
GCST006979_480	Heel bone mineral density	2.000000e-11
GCST007202_15	High density lipoprotein cholesterol levels	6.000000e-06
GCST011066_4	Motor fluctuations in levodopa treated Parkinson’s disease	9.000000e-06
GCST011108_2	Colorectal cancer x fine particulate matter exposure levels interaction	2.000000e-09
GCST90002404_228	Red cell distribution width	2.000000e-21

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0010747	response to levodopa
EFO:0010749	motor function measurement
EFO:0008255	particulate matter air pollution measurement
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3981 (SINGLE PROTEIN), CHEMBL4888459 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

79 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 469,629 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1173655	AFATINIB	4	15,144
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1289494	TIVOZANIB	4	4,455
CHEMBL1289601	LENVATINIB	4	8,784
CHEMBL1289926	AXITINIB	4	15,732
CHEMBL1336	SORAFENIB	4	86,060
CHEMBL180022	NERATINIB	4	9,404
CHEMBL2035187	PACRITINIB	4	3,345
CHEMBL24828	VANDETANIB	4	42,230
CHEMBL255863	NILOTINIB	4	38,627
CHEMBL288441	BOSUTINIB	4	12,255
CHEMBL3301607	FILGOTINIB	4	2,905
CHEMBL3301610	ABEMACICLIB	4	7,045
CHEMBL3301622	GILTERITINIB	4	2,395
CHEMBL3545311	BRIGATINIB	4	5,634
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL5416410	DASATINIB	4	655
CHEMBL553	ERLOTINIB	4	108,300
CHEMBL554	LAPATINIB	4
CHEMBL576982	QUIZARTINIB	4
CHEMBL601719	CRIZOTINIB	4
CHEMBL608533	MIDOSTAURIN	4
CHEMBL939	GEFITINIB	4
CHEMBL2087361	ICOTINIB	3
CHEMBL2105728	CRENOLANIB	3
CHEMBL217092	SARACATINIB	3
CHEMBL223360	LINIFANIB	3
CHEMBL270995	BRIVANIB ALANINATE	3

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — SLK subfamily

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
DDR1/2 inhibitor 5n	Inhibition	8.0	pKd
bosutinib	Inhibitor	7.28	pIC50

Binding affinities (BindingDB)

1 measured of 2 human assays (2 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
3-[2-(cyclopropanecarbonylamino)-[1,3]thiazolo[5,4-b]pyridin-5-yl]-N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide	KD	57 nM	US-8765747: Fused 2-aminothiazole compounds

ChEMBL bioactivities

255 potent at pChembl≥5 of 265 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.52	Kd	0.03	nM	STAUROSPORINE
10.43	Kd	0.037	nM	STAUROSPORINE
9.28	Kd	0.53	nM	FORETINIB
9.04	Kd	0.92	nM	AST-487
8.52	Kd	3	nM	UCN-01
8.24	Kd	5.7	nM	LESTAURTINIB
8.23	Kd	5.9	nM	BAY-826
8.16	IC50	6.93	nM	STAUROSPORINE
8.15	Kd	7.1	nM	DORAMAPIMOD
8.15	Kd	7	nM	BOSUTINIB
8.04	IC50	9.01	nM	STAUROSPORINE
8.02	Kd	9.5	nM	CHEMBL2148124
8.00	Kd	10	nM	CHEMBL4168305
8.00	Kd	10	nM	CHEMBL4571241
7.92	IC50	12	nM	CHEMBL156277
7.92	Kd	12	nM	DORAMAPIMOD
7.89	Kd	13	nM	NERATINIB
7.89	Kd	13	nM	KW-2449
7.85	Kd	14	nM	CHEMBL3688339
7.81	IC50	15.6	nM	STAUROSPORINE
7.72	Kd	19	nM	ERLOTINIB
7.72	Kd	19	nM	SUNITINIB
7.66	Kd	22	nM	CHEMBL1908396
7.64	IC50	23	nM	CHEMBL4875188
7.64	Kd	23	nM	CEDIRANIB
7.58	Ki	26	nM	CHEMBL4875188
7.49	Kd	32.12	nM	CHEMBL5653589
7.46	Ki	35	nM	CHEMBL4878325
7.46	ED50	35.08	nM	CHEMBL5653589
7.36	Kd	44	nM	CRIZOTINIB
7.34	Ki	46	nM	CHEMBL156277
7.33	Ki	47	nM	CHEMBL4877889
7.33	IC50	47	nM	REBASTINIB
7.28	IC50	52	nM	BOSUTINIB
7.24	Kd	57	nM	CHEMBL5084426
7.22	IC50	60	nM	CHEMBL4878325
7.22	Kd	60	nM	RAF-265
7.21	Ki	61	nM	CHEMBL4856751
7.16	Kd	70	nM	R-406
7.16	Kd	69	nM	GSK-461364
7.15	Kd	71	nM	DECERNOTINIB
7.14	Ki	73	nM	CHEMBL157089
7.12	Ki	76	nM	CHEMBL4855513
7.11	Kd	77	nM	CHEMBL1241674
7.09	Kd	81	nM	VANDETANIB
7.09	Kd	82	nM	AT-9283
7.09	Kd	82	nM	TAE-684
7.08	Kd	83	nM	ERLOTINIB
7.08	Ki	84	nM	CHEMBL4869745
7.08	Kd	84	nM	PAZOPANIB

PubChem BioAssay actives

247 with measured affinity, of 1298 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	256604: Average Binding Constant for STK10; NA=Not Active at 10 uM	kd	<0.0001	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	625030: Binding constant for LOK kinase domain	kd	0.0005	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	435677: Binding constant for LOK kinase domain	kd	0.0009	uM
(2S,3R,4R,6R,18S)-18-hydroxy-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1425177: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0030	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507591: Binding affinity to LOK	kd	0.0057	uM
3-cyano-N-[2,4-dimethyl-5-(6-pyridin-3-ylimidazo[2,1-e]pyrazol-1-yl)phenyl]-5-(pentafluoro-lambda6-sulfanyl)benzamide	2155086: Binding affinity to LOK (unknown origin) assessed as dissociation constant by KINOME scan assay	kd	0.0059	uM
Bosutinib	625030: Binding constant for LOK kinase domain	kd	0.0070	uM
1-[3-tert-butyl-1-(4-methylphenyl)pyrazol-5-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea	256604: Average Binding Constant for STK10; NA=Not Active at 10 uM	kd	0.0071	uM
N-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-3-fluorophenyl]-6-ethyl-1,2-dimethyl-4-oxoquinoline-3-carboxamide	1626965: Binding affinity to human LOK	kd	0.0100	uM
3-(2-imidazo[1,2-a]pyrazin-3-ylethynyl)-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-4-propan-2-ylbenzamide	1356736: Binding affinity to human LOK	kd	0.0100	uM
N-[3-[2-[4-(2-aminoethoxy)anilino]quinazolin-6-yl]-4-methylphenyl]-3-(trifluoromethyl)benzamide	1799897: Fluorescence Assay from Article 10.1021/cb300623a: “A Hexylchloride-Based Catch-and-Release System for Chemical Proteomic Applications.”	ic50	0.0100	uM
3-(3-chloroanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779843: Inhibition of STK10 (unknown origin) expressed in Sf9 cells assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method	ic50	0.0120	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	625030: Binding constant for LOK kinase domain	kd	0.0130	uM
Neratinib	625030: Binding constant for LOK kinase domain	kd	0.0130	uM
1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone	1425177: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0140	uM
Erlotinib	435677: Binding constant for LOK kinase domain	kd	0.0190	uM
Sunitinib	435677: Binding constant for LOK kinase domain	kd	0.0190	uM
1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea	625030: Binding constant for LOK kinase domain	kd	0.0220	uM
3-[[4-(2-methoxyphenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779843: Inhibition of STK10 (unknown origin) expressed in Sf9 cells assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method	ic50	0.0230	uM
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline	625030: Binding constant for LOK kinase domain	kd	0.0230	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149507: Binding affinity to human STK10 incubated for 45 mins by Kinobead based pull down assay	kd	0.0321	uM
3-[[4-(4-bromo-2-methoxyphenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.0350	uM
Crizotinib	625030: Binding constant for LOK kinase domain	kd	0.0440	uM
3-(2-methoxyphenyl)-4-(naphthalen-1-ylamino)pyrrole-2,5-dione	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.0470	uM
4-[4-[(3-tert-butyl-1-quinolin-6-ylpyrazol-5-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide	2168214: Inhibition of human LOK preincubated for 2 hrs followed by ATP addition and measured every 2 mins for 2.5 hrs by spectrophotometric analysis	ic50	0.0470	uM
1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine	435677: Binding constant for LOK kinase domain	kd	0.0600	uM
3-[[4-(5-bromo-2-methoxyphenyl)-2,5-dioxopyrrol-3-yl]amino]benzonitrile	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.0610	uM
5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide	625030: Binding constant for LOK kinase domain	kd	0.0690	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	625030: Binding constant for LOK kinase domain	kd	0.0700	uM
(2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide	1425177: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0710	uM
3-(3-chloro-4-hydroxyanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.0730	uM
3-(3-fluoroanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.0760	uM
2-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol	625030: Binding constant for LOK kinase domain	kd	0.0770	uM
Vandetanib	435677: Binding constant for LOK kinase domain	kd	0.0810	uM
1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea	1425177: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0820	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	625030: Binding constant for LOK kinase domain	kd	0.0820	uM
Pazopanib	435677: Binding constant for LOK kinase domain	kd	0.0840	uM
3-(1,3-benzodioxol-5-ylamino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.0840	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	625030: Binding constant for LOK kinase domain	kd	0.0870	uM
N-[4-[4-(3-cyanoanilino)-2,5-dioxopyrrol-3-yl]-3-methoxyphenyl]-2-methylpropanamide	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.0880	uM
5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid	1425177: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0960	uM
3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate	1779843: Inhibition of STK10 (unknown origin) expressed in Sf9 cells assessed as transfer of radiolabelled phosphate group from ATP by reaction biology method	ic50	0.0990	uM
3-(2-methoxyphenyl)-4-(3-methylsulfanylanilino)pyrrole-2,5-dione	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.1100	uM
3-(2-methoxyphenyl)-4-(quinolin-6-ylamino)pyrrole-2,5-dione	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.1100	uM
3-[(4-naphthalen-1-yl-2,5-dioxopyrrol-3-yl)amino]benzonitrile	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.1100	uM
4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide	435677: Binding constant for LOK kinase domain	kd	0.1100	uM
(E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide	256604: Average Binding Constant for STK10; NA=Not Active at 10 uM	kd	0.1100	uM
3-(4-methoxyanilino)-4-(2-methoxyphenyl)pyrrole-2,5-dione	1779840: Binding affinity human STK10 by binding displacement assay	ki	0.1200	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	435677: Binding constant for LOK kinase domain	kd	0.1200	uM
Brigatinib	2182831: Inhibition of human STK10 using RLGRDKYKTLRQIRQ as substrate in presence of [gamma33P]-ATP by HotSpot assay	ic50	0.1230	uM

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	decreases expression, increases expression, affects expression	3
Benzo(a)pyrene	affects methylation, decreases expression	2
Estradiol	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	increases expression	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
coumarin	affects phosphorylation	1
N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
azoxystrobin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
calfactant	affects cotreatment, decreases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
bisphenol S	affects cotreatment, increases methylation	1
picoxystrobin	decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Aspirin	affects response to substance	1
Caffeine	decreases phosphorylation	1
Ethyl Methanesulfonate	increases expression	1
Ivermectin	decreases expression	1
Methapyrilene	increases methylation	1

ChEMBL screening assays

308 unique, capped per target: 308 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1004492	Binding	Binding affinity to human recombinant LOK expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry	Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. — Bioorg Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2HM	Abcam HeLa STK10 KO	Cancer cell line	Female
CVCL_TQ69	HAP1 STK10 (-) 1	Cancer cell line	Male
CVCL_TQ70	HAP1 STK10 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.